Cited by 794Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The publisher hasn’t deposited this paper’s reference list.

Sorted by citations

Items 701–794 of 794

Sepsis: Partial least squares structural equation modelling (PLS-SEM) suggests a critical role for anti-inflammatory responses in clinical severityPreprint
Mukherjee, R., Barman, P. K., Thatoi, P. K., Prusty, B. K., Tripathy, R., Das, B. K., & Ravindran, B. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/193615 · Cited by 1
Relative adrenal insufficiency is a risk factor and an endotype of sepsis - A proof of concept study to support a precision medicine approach for glucocorticoid sepsis therapyPreprint
Wu, C.-H., Guo, L., Wang, Q., Ye, X., Mineo, C., Shaul, P. W., & Li, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.16.043976 · Cited by 1
Host Genetic Susceptibility to Infection
Ladhani, S. N., & Booy, R. (2008) · Springer eBooks · doi:10.1007/978-1-84628-917-0_9 · Cited by 1
Shock States and Nitric Oxide
Ruetten, H., & Thiemermann, C. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-002-5_19 · Cited by 1
Endotoxin Antagonists
Dunn, D. L. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_48 · Cited by 1
What is new in sepsis therapy?
(1997) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1997.tb04899.x · Cited by 1
Editorial
Morrison, D. C. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200301 · Cited by 1
Adjunctive and Supportive Measures for Community-Acquired Pneumonia
WATERER, G. W., & Wunderink, R. G. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1679-8_39 · Cited by 1
Fluoxetine promotes immunometabolic defenses to mediate host-pathogen cooperation during sepsisPreprint
Gallant, R. M., Snyder, J. M., & Ayres, J. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.18.567681 · Cited by 1
“Indeed, numerous clinical trials have been performed with neutralizing antibodies that target pro-inflammatory cytokines, however such approaches have been met with little success (Fisher, 1994; Fisher et al., 1996; Gotts and Matthay, 2016; Hotchkiss et al., 2016; Panacek et al., 2004).”
Background
Mediatorblockade in der Sepsis: Inhibitoren, Antagonisten und Antikörper
Seeger, W., Grimminger, F., & WALMRATH, D. (2000) · Springer eBooks · doi:10.1007/978-3-662-07962-1_9 · Cited by 1
Septic Myocardial Dysfunction: Role of Cytokines and Nitric Oxide
Kumar, A., & Parrillo, J. E. (1997) · Yearbook of intensive care and emergency medicine · doi:10.1007/978-3-662-13450-4_24 · Cited by 1
Management of Respiratory Failure in Severe Community-Acquired Pneumonia
Dellinger, R. P. (2001) · Perspectives on critical care infectious diseases · doi:10.1007/978-1-4615-1631-6_1
Receptor Blocking Agents: Why Did They Fail?
Berlot, G., & Soiat, M. (1998) · Springer eBooks · doi:10.1007/978-88-470-2278-2_55
At the Interface of Statistics and Medicine: Conflicting Paradigms
Byers, V. S., & Gorelick, K. J. (1997) · Springer eBooks · doi:10.1007/978-1-4612-1880-7_7
Disturbances and Modulators of Coagulation and Fibrinolysis in Sepsis
THIJS, L. G. (1998) · Springer eBooks · doi:10.1007/978-88-470-2271-3_10
Störungen der Blutgerinnung und Fibrinolyse
Vervloet, M. G., THIJS, L. G., Hack, C. E., et al. (2000) · Springer eBooks · doi:10.1007/978-3-662-07962-1_12
Lights and Shadows in Sepsis and Multiple Organ Dysfunction Syndrome (MODS)
Berlot, G., Silvestri, L., Iscra, F., et al. (1998) · Springer eBooks · doi:10.1007/978-88-470-2271-3_16
Thirty Years of Monoclonal Antibodies: A Long Way to Pharmaceutical and Commercial Success
Gottschalk, U., & Mundt, K. (2005) · doi:10.1002/9783527620982.ch47
Factors Influencing the Efficacy of Mediator‐Specific Anti‐Inflammatory, Glucocorticoid, and Anticoagulant Therapies for Sepsis
Minneci, P. C., Deans, K. J., Haley, M., Cui, X., Natanson, C., & Eichacker, P. Q. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse021
Measuring the Biological Efficacy of Mediator-Directed Therapy
Pinsky, M. R. (1997) · Sepsis · doi:10.1023/a:1009723604209
Recent Advances in the Pathophysiology and Treatment of Septic Shock
Simon, G. L. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4217-9_9
Clinical Trials of Mediator-Targeted Therapy in Sepsis
Marshall, J. C. (2000) · Springer eBooks · doi:10.1007/978-88-470-2284-3_18
Gene therapy — an alternative approach for anti-cytokine therapies
Rogy, M. A. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8755-7_18
Sepsis and MODS - What Is Wrong and What Is Right
Gullo, A., & Berlot, G. (1999) · Springer eBooks · doi:10.1007/978-88-470-2248-5_8
Drotrecogin Alfa Activated (Recombinant Human Activated Protein C , Xigris)
Suh, B., & Samuel, R. (2011) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse444
Verminderung kardiovaskulärer Störungen durch perioperative Antihistaminikaprophylaxe in der Allgemeinchirurgie: Sind die Medikamente austauschbar?
Celik, I., Stinner, B., Lorenz, W., et al. (1998) · Springer eBooks · doi:10.1007/978-3-642-72182-3_151
Can second-generation versions of existing therapeutics be successful in clinical trials of sepsis?
Fisher, C. J. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200314
Self-citation
Future opportunities for nonantibiotic prevention or adjunctive therapy of neonatal bacterial infections
Fakler, C. R., & Weisman, L. E. (1999) · Seminars in Pediatric Infectious Diseases · doi:10.1016/s1045-1870(99)80044-2
Effets de l'épuration extrarénale continue et discontinue sur les médiateurs de l'inflammation
Journois, D. (1998) · Réanimation Urgences · doi:10.1016/s1164-6756(98)80051-0
Monocyte B7 and Sialyl Lewis X modulates the efficacy of IL‐10 down‐regulation of LPS‐induced monocyte tissue factor in whole blood
Warnes, G., Biggerstaff, J., & Francis, J. L. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00788.x
Évaluation critique des traitements non anti-infectieux du sepsis : quelles leçons tirer du passé ?
Montravers, P., Lasocki, S., Séguin, P., et al. (2007) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2007.01.015
Protection from death in endotoxin shock: Does fish oil need a LIF? *
Haynes, B. F., & Sempowski, G. D. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00045
Mortality in Sepsis
Matot, I., & Sprung, C. L. (1997) · Springer eBooks · doi:10.1007/978-88-470-2296-6_37
Tumor Necrosis Factor _ and Interleukin-1_ Inhibitory Therapies
KIPS, J. C., & PAUWELS, R. A. (2002) · Lung biology in health and disease · doi:10.1201/b14066-11
Using Secondary Data in Statistical Analysis
Freeman, B. D., BANKS, S., & Natanson, C. (2007) · Elsevier eBooks · doi:10.1016/b978-012369440-9/50023-2
Experimental models for acute kidney injury
Nakano, D. (2016) · Folia Pharmacologica Japonica · doi:10.1254/fpj.148.163
10.1016/s0186-159x(08)55043-1
Frazier, W. J., & Hall, M. W. (2000) · Time to knit · doi:10.1016/s0186-159x(08)55043-1
Sepsis: Staging and Potential Future Therapies
Lehmann, C., Zhou, J., & Caldwell, C. C. (2017) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00157ed1v01y201708isp077
Embracing Enrichment and Unknown Unknowns*
Wong, H. R. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002781
Severe Sepsis and Multiple Organ Dysfunction
Zanotti-Cavazzoni, S. L., Dellinger, R. P., & Parrillo, J. E. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50028-5
The Role of Mitochondrial Dysfunction in Sepsis: What Is New?
Wang, Y., Chakraborty, M., & McLean, A. S. (2019) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-030-06067-1_41
Using Secondary Data in Statistical Analysis
Freeman, B. D., Gerstenberger, E. P., Banks, S., et al. (2002) · Elsevier eBooks · doi:10.1016/b978-012274065-7/50018-6
Zelluläre Pathomechanismen der akuten Pankreatitis
Sendler, M., & Lerch, M. M. (2020) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-020-00079-1
Has outcome in sepsis improved? What works? What does not?
Vincent, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64068-8.00048-1
Basics of Hemodynamic Measurements
Magder, S. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-73387-2_22
Non-renal indication of continuous renal replacement therapies
Journois, D., & Playe, E. (1998) · Springer eBooks · doi:10.1007/978-94-011-5482-6_107
Therapy of Sepsis Syndrome with Human Polyclonal IgM-Enriched Immunoglobulins: Interim Analysis of a Randomized Trial in Neutropenic Cancer Patients
Behre, G., Ostermann, H., Rothenburger, M., et al. (1997) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-60377-8_153
The Immunology of Sepsis
Parker, S. J., & Windsor, A. C. J. (2002) · Springer eBooks · doi:10.1007/978-1-4471-0201-4_3
Zanamivir,: ¿un nuevo tratamiento antigripal?
Cerrada, E., Linares, J. O., & Voces, D. (2000) · FMC - Formación Médica Continuada en Atención Primaria
Anticytokine Therapies in Patients with Severe Sepsis and Septic Shock
Bochud, P., Glauser, M. P., & Calandra, T. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-309-5_26
Fluid Resuscitation
Fontana, J. R., & Rainey, T. G. (2001) · Springer eBooks · doi:10.1007/978-1-4757-6645-5_4
IMMUNOMODULATING AGENTS
Pine, T. R. L., & Hill, H. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50259-4
New Therapies for Sepsis
Whittaker, L., & Nadel, S. (2008) · Springer eBooks · doi:10.1007/978-1-84628-917-0_17
Consumption coagulopathy
Chierego, M. L., & Gullo, A. (2003) · Springer eBooks · doi:10.1007/978-88-470-2215-7_43
Reply
Dunn, D. L., Phillips, J., & Weiss, C. A. (2001) · Surgery · doi:10.1067/msy.2001.112549
Hypovolämischer Schock
Brückner, U. B. (1997) · Springer eBooks · doi:10.1007/978-3-642-60765-3_26
ANSWER
(2007) · Thorax · doi:10.1136/thx.2007.088237a
Antithrombin III
Schuster, H.-P., & Knaub, S. (2000) · Springer eBooks · doi:10.1007/978-3-662-07962-1_8
The Colon
Wittmann, D. H. (2003) · Springer eBooks · doi:10.1007/978-3-642-55914-3_22
Ulinastatin and thymosin as immune modulators for the treatment of sepsis
Luo, P. F., Ren, Y. T., Liu, Y., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009940.pub2
Choc septique
Carpentier, J.-P., Pouliquen, G., & Petrognani, R. (2004) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(01)00055-2
Medical Applications of Recombinant Proteins in Humans and Animals
Wetzel, G. D. (1998) · Biotechnology · doi:10.1002/9783527620869.ch5
Sepsis Definitions
Pérez, J., & Dellinger, R. P. (2001) · Perspectives on critical care infectious diseases · doi:10.1007/978-1-4615-1581-4_1
Avaliação da via de necroptose em pacientes com sepse e sua correlação com a gravidade e parâmetros clínicos desta enfermidade
Jolvino, D. (2019) · doi:10.31744/pg2019.106812
Management of Dysregulated Immune Response in the Critically Ill: Heart and Circulation
Deniau, B., de Roquetaillade, C., Mebazaa, A., & Chousterman, B. G. (2023) · Lessons from the ICU · doi:10.1007/978-3-031-17572-5_10
Immune mechanisms in the pathogenesis of acute peritonitis G.V. Bulava
Булава, Г. В. (2023) · Transplantologiya The Russian Journal of Transplantation · doi:10.23873/2074-0506-2023-15-1-89-97
Development of network pharmacology in sepsis treatmentPreprint
chen, F., & chen, M. (2023) · doi:10.22541/au.168491380.08715576/v1
Clinical Case Abstracts
Jørgensen, N. M., & Larsen, L. (2023) · HIV Medicine · doi:10.1111/hiv.13574
Eficacia de la terapia hemoadsortiva combinada con hemofiltración de alto volumen en el manejo del shock séptico refractario
Kemeny, R., Giglio, A., Ramos, A., et al. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2023.10.003
10.1016/s1166-8598(20)30246-5
(2000) · Time to knit · doi:10.1016/s1166-8598(20)30246-5
10.1016/s0246-0289(19)30139-2
(2000) · Time to knit · doi:10.1016/s0246-0289(19)30139-2
10.1016/s0246-0289(19)30120-3
(2000) · Time to knit · doi:10.1016/s0246-0289(19)30120-3
Research Progress on Diagnosis and Treatment of Hemophagocytic Syndrome
丁, 永. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541251
Immunomodulating Agents
Furst, L. E., Hill, H. R., & Lapine, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00258-2
Bacteremia and Septic Shock
Kaplan, S. L., & Vallejo, J. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00065-0
Normal and Impaired Immunologic Responses to Infection
Tosi, M. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00002-9
Endothelial Control of the Inflammatory Process
Adam, A. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-55254-0_9-1
Srpx2 exerts multifaceted cardio-protection in septic cardiomyopathy: PI3K/AKT-dependent attenuation of mitochondrial oxidative stress, apoptotic signaling, and inflammatory response
Guo, Y., Liu, Y., Zhou, M., et al. (2025) · Human Cell · doi:10.1007/s13577-025-01306-8
Activation of Nuclear Factor-кB in Sepsis and ARDS
Christman, J. W., Blackwell, T. S., & Clark, M. (1997) · Yearbook of intensive care and emergency medicine · doi:10.1007/978-3-662-13450-4_3
The Design of Transfusion in Randomised Controlled Trials in Critically Ill Patients
Hébert, P. C. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5619-0_22
Utility of Animal Models of Pneumonia and Sepsis
Taenaka, H., Maishan, M., Watanabe, R., & Matthay, M. A. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.11.005 · Cited by 1
Immunology of Sepsis
Morrell, E. D., & Mikacenic, C. R. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.11.003 · Cited by 1
Safety of intravenous use of anakinra in pediatric inflammatory conditions: a retrospective multicenter study
Klanjscek, M., Trevisan, M., Pastore, S., Pardeo, M., Tommasini, A., Caorsi, R., Dell'Orso, G., Rumeileh, S. A., Conti, C., D'Ippolito, C., et al. (2026) · Pediatric Rheumatology Online Journal · doi:10.1186/s12969-026-01199-3
Effet de la combinaison de l'hypertension et de l'infarctus du myocarde sur la physiopathologie du choc septique : mise au point d'un modèle animal expérimental mimant le phénotype des patients septiques
Kattani, N. A. (2016) · theses.fr (ABES) · doi:10.70675/820b9010zbacaz40a2za64az252da03fcebb
Apport de la transcriptomique dans la compréhension et la prise en charge des états septiques sévères
Turrel-Davin, F. (2011) · theses.fr (ABES) · doi:10.70675/9de36ffcz654bz4cc6z8ca9z6c25ac664abe
In vitro and in vivo study of the effects of Levetiracetam on activated microglia during sepsis
Fleurance, R. (2021) · theses.fr (ABES) · doi:10.70675/0a82ed6ez6595z4366z832fz70cbe839c7ff
Effet de l'inhibition ciblée des interférons de type I sur l'endothélium vasculaire au cours du sepsis
Clère-Jehl, R. (2020) · theses.fr (ABES) · doi:10.70675/a65a57a6ze1d1z47baz8fa5zabef17722df4
Propriétés immunes de la cellule endothéliale au cours du sepsis
Pons, S. (2021) · theses.fr (ABES) · doi:10.70675/3999fc10z25d2z4513z87dazc18894ab82dd
Implication de l'axe C5a-C5aR1 dans l'orage inflammatoire des formes sévères de COVID-19 de l'adulte
Carvelli, J. (2023) · theses.fr (ABES) · doi:10.70675/be12640bzc919z4322zb146z5a584bd7ec67
Étude physiopathologique des interactions entre dysfonctions circulatoires et médiateurs de l’inflammation : évaluation du potentiel thérapeutique du pimobendane et d’une nouvelle membrane d’hémofiltration dans un modèle porcin de sepsis
Slek, C. (2024) · theses.fr (ABES) · doi:10.70675/c92aeb34z4bf6z4ac1z8b86z05b8b0931355
Update on sepsis treatment
Chiscano‐Camón, L., Ruiz‐Rodríguez, J. C., Ruiz‐Sanmartín, A., Nicolás-Morales, P., Hernández-González, M., & Ferrer, R. (2026) · Journal of Intensive Care · doi:10.1186/s40560-026-00898-z
When to initiate immunomodulatory therapy in sepsis
Wen, Y., & Huang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1898450 · Cited by 1
Genetic associations in sepsis and ARDS
Moroniti, J. J., Rameshchandran, P. M., Guo, M., Labuda, V., Chandy, M., & Leligdowicz, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1864880
“Relative to placebo, rIL1Ra dosing of 1 and 2 mg/kg per hour reduced 28-day mortality by 9% and 15%, respectively, without reaching statistical significance (Fisher et al., 1994).”
Hemolytically Active (Acylated) Alpha-Hemolysin Elicits Interleukin-1β (IL-1β) but Augments the Lethality ofEscherichia coliby an IL-1- and Tumor Necrosis Factor-Independent Mechanism
Gleason, T. G., Houlgrave, C. W., May, A. K., et al. (1998) · Infection and Immunity · doi:10.1128/iai.66.9.4215-4221.1998

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks